Llp «abdi Ibrahim Global Pharm» (aigp

Aigp, established in 2012, is a prominent pharmaceutical company operating within the Healthcare and Pharmaceuticals sectors. Headquartered in Almaty, Kazakhstan, the company focuses on developing and manufacturing over 100 distinct medical treatments. These treatments address critical health conditions including diabetes, tuberculosis, HIV, and various heart diseases, underscoring Aigp's commitment to public health. The company's strategic vision centers on improving healthcare access and providing affordable medication solutions.

With an employee range of 500-1,000 employees, Aigp demonstrates significant operational scale. Its annual revenue stands at $41.7M, reflecting its market presence. While the provided data indicates a single primary location, Aigp actively exports its pharmaceutical products to multiple international markets, including Azerbaijan, Uzbekistan, Afghanistan, and Georgia. This global reach is complemented by its close collaboration with government health programs within Kazakhstan, ensuring wider availability of essential medicines. To understand the driving force behind these operations, one can Meet Aigp's team.

Aigp's product portfolio is designed to tackle serious health challenges, offering vital therapeutic options for chronic and infectious diseases. The company's dedication to affordability is a key aspect of its business model, particularly in its work with government initiatives aimed at enhancing healthcare accessibility for populations in need. By focusing on both innovation in treatment development and equitable distribution, Aigp plays a crucial role in the regional and international pharmaceutical landscape.